Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement

Phase 2

Completed

Conditions: Behcet Disease

Interventions: Drug: Canakinumab

First Posted Date: 2016-04-29

Last Posted Date: 2020-06-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT02756650

Locations: 🇹🇷
Novartis Investigative Site, Istanbul, Turkey

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

Completed

Conditions: HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer

First Posted Date: 2016-04-28

Last Posted Date: 2023-02-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 440

Registration Number: NCT02753686

Locations: 🇨🇦
Novartis Investigative Site, Quebec, Canada

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

Phase 4

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Secukinumab

First Posted Date: 2016-04-27

Last Posted Date: 2019-09-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1660

Registration Number: NCT02752776

Locations: 🇬🇧
Novartis Investigative Site, Wellingborough, United Kingdom

Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis

Phase 3

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.

First Posted Date: 2016-04-25

Last Posted Date: 2019-09-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT02750592

Locations: 🇯🇵
Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan

Study of Secukinumab With 2 mL Pre-filled Syringes

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Secukinumab 2 mL form
Drug: Secukinumab 1 mL form
Drug: Placebo

First Posted Date: 2016-04-22

Last Posted Date: 2019-07-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 214

Registration Number: NCT02748863

Locations: 🇬🇧
Novartis Investigative Site, Surrey, United Kingdom

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Biological: Secukinumab
Biological: Adalimumab

First Posted Date: 2016-04-20

Last Posted Date: 2021-01-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 853

Registration Number: NCT02745080

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

Phase 1

Completed

Conditions: Solid Tumors
Lymphomas

Interventions: Drug: GWN323
Drug: PDR001

First Posted Date: 2016-04-15

Last Posted Date: 2021-02-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 92

Registration Number: NCT02740270

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Phase 1

Terminated

Conditions: Advanced or Metastatic ER+ Breast Cancer

Interventions: Drug: LSZ102
Drug: LEE011
Drug: BYL719

First Posted Date: 2016-04-12

Last Posted Date: 2022-08-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 199

Registration Number: NCT02734615

Locations: 🇺🇸
MD Anderson Cancer Center SC - LSZ102X2101, Houston, Texas, United States
🇺🇸
Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: Everolimus
Drug: Exemestane

First Posted Date: 2016-04-08

Last Posted Date: 2021-05-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 104

Registration Number: NCT02732119

Locations: 🇺🇸
Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
St. Luke's Cancer Institute Regulatory, Kansas City, Missouri, United States
🇺🇸
Research Medical Center HCA Midwest Division, Kansas City, Missouri, United States

and more 22 locations

Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement

Phase 3

Completed

Conditions: Axial Psoratic Arthritis

Interventions: Biological: Secukinumab
Drug: Secukinumab and Placebo

First Posted Date: 2016-03-29

Last Posted Date: 2020-10-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 503

Registration Number: NCT02721966

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy